Cover Image
市場調查報告書

眼科的遺傳基因療法的考察:開發平台評估、技術趨勢、競爭情形

Gene Therapy Ophthalmology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2017

出版商 DelveInsight Business Research LLP 商品編碼 524524
出版日期 內容資訊 英文 188 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
眼科的遺傳基因療法的考察:開發平台評估、技術趨勢、競爭情形 Gene Therapy Ophthalmology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2017
出版日期: 2017年07月01日 內容資訊: 英文 188 Pages
簡介

本報告提供現在開發中的眼科的遺傳基因療法產品的相關調查,眼科的遺傳基因療法產品概要,各公司、研究機關中開發中的眼科的遺傳基因療法產品的開發平台情形,產品的競爭情形,各階段的開發平台分析,新興趨勢,開發中產品比較分析,最新的開發技術亮點,市場成長的推動要素與阻礙等系統性資訊。

目錄

  • 調查概要
  • 摘要整理
  • 概要
  • 遺傳基因療法及眼科
  • 基因轉移系
  • 腺病毒:有效率的載體
  • 競爭情形
  • 合作、契約額
  • 開發技術
  • 遞送系統為基礎的眼科的遺傳基因療法產品
  • 眼科的遺傳基因療法產品:各適應症
  • 開發平台治療藥 (公司提供)
  • 比較分析
  • 後期階段產品 (現場、第三階段)
  • 中期階段產品 (第二階段)
  • 比較分析
  • 初期階段產品 (第一階段、IND)
  • 比較分析
  • 前臨床、藥物研發階段產品
  • 比較分析
  • 藥物候補藥簡介
  • SAR 421869: Sanofi
  • 產品說明
  • 研究開發
  • 產品開發活動
  • NSR AAV-RPGR: NightstaRx Limited
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 治療評估:活性產品 (公司提供)
  • 評估:單劑療法產品
  • 評估:給藥途徑
  • 評估:階段、給藥途徑
  • 評估:階段、分子類型
  • 中止的產品
  • 比較分析
  • 藥物名:企業名
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 暫停中的產品
  • 比較分析
  • 藥物名:企業名
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 研究活動:各企業
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 市場障礙、促進要素
  • 促進要素
  • 抑制因素
  • SWOT分析
  • 附錄
  • 調查手法
  • 諮詢服務
  • 免責聲明
  • 關於DelveInsight

圖表清單

目錄
Product Code: DISR0012

DelveInsight's report, "Gene Therapy Ophthalmology Insight - Pipeline Assessment, Market Trend, Technology and Competitive Landscape, 2017" emphasizes on the currently under development Gene Therapy products in Opthalmology.

The report covers 15+ companies, which are active in this field with 42 products and various technologies. This report includes: Gene Therapy products in Ophthalmology by companies and Research Activities by Institutes in this area. The report provides in-depth analysis of the product profiles covering their pre-clinical and clinical studies, collaboration details and deal values, technologies and targeted indications. The report further gives information on market drivers and barriers followed by the SWOT Analysis.

Scope:

  • Overview of the Gene Therapy products in Ophthalmology
  • Pipeline scenario of Gene Therapy products in Ophthalmology under development different companies and research institutes
  • Competitive landscape of products
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles including: mechanism of action, route of administration and molecule type along with product development activities
  • Coverage of licensors, collaborators and development partners, deal terms and deal values
  • Highlights of latest developmental technologies for Gene Therapy products in Ophthalmology
  • Market drivers and barriers along with the SWOT analysis

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Delve Insight's team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and access to available databases.

Table of Contents

Report Introduction

Executive Summary

Overview

Gene Therapy and Ophthalmology

Gene Transfer Systems

Adenovirus: An Efficient Vector

Competitive Landscape

Collaborations and Deal values

Designation Analysis

Developmental Technologies

Gene Therapy products in Ophthalmology on the basis of Delivery System

Gene Therapy Products in Ophthalmology by Indication

Pipeline Therapeutics (Company Sponsored)

Comparative Analysis

Late Stage Products (Filed and Phase III)

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I and IND)

Comparative Analysis

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Candidate Profiles

SAR 421869: Sanofi

Product Description

Research and Development

Product Development Activities

NSR AAV-RPGR: NightstaRx Limited

Product Description

Research and Development

Product Development Activities

Therapeutic Assessment: Active Products (Company Sponsored)

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Stage and Molecule Type

Discontinued Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Dormant Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Research Activities by Institutions

Drug Name: Institute Name

Product Description

Research and Development

Product Development Activities

Market Barriers and Drivers

Drivers

Barriers

SWOT Analysis

Appendix

Methodology

Consulting Services

Disclaimer

Report Purchase Options

About DelveInsight

List of Tables

  • Table 1: Characteristic features of gene transfer viral vectors
  • Table 2: Collaboration and Deal Values for Gene Therapies in Ophthalmology
  • Table 3: Designation Analysis for Gene Therapies in Ophthalmology
  • Table 4: Companies and their Technologies for Gene Therapies in Ophthalmology
  • Table 5: Gene Therapy products in Ophthalmology on the basis of Delivery System
  • Table 6: Gene Therapy Products in Ophthalmology by Indication
  • Table 7: Total Products for Gene Therapy Ophthalmology
  • Table 8: Late Stage Products (Filed and Phase III)
  • Table 9: Mid Stage Products (Phase II)
  • Table 10: Early Stage Products (Phase I and IND)
  • Table 11: Pre-clinical and Discovery Stage Products
  • Table 12: Assessment by Monotherapy Products
  • Table 13: Assessment by Route of Administration
  • Table 14: Assessment by Stage and Route of Administration
  • Table 15: Assessment by Stage and Molecule Type
  • Table 16: Discontinued Products
  • Table 17: Dormant Products

List of Figures

  • Figure 1: Gene Therapy Administration in Ophthalmology
  • Figure 2: Designation Analysis for Gene Therapies in Ophthalmology
  • Figure 3: Gene Therapy products in Ophthalmology on the basis of Delivery System
  • Figure 4: Total Products for Gene Therapy Ophthalmology
  • Figure 5: Late Stage Products (Filed and Phase III)
  • Figure 6: Mid Stage Products (Phase II)
  • Figure 7: Early Stage Products (Phase I and IND)
  • Figure 8: Pre-clinical and Discovery Stage Products
  • Figure 9: Assessment by Monotherapy Products
  • Figure 10: Assessment by Route of Administration
  • Figure 11: Assessment by Stage and Route of Administration
  • Figure 12: Assessment by Stage and Molecule Type
  • Figure 13: Discontinued Products
  • Figure 14: Dormant Products
Back to Top